Tigecycline for Treatment of Rapidly Growing Mycobacteria

The University of Texas Health Science Center at Tyler8 enrolled

Overview

To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients with rapidly growing mycobacterial disease (especially M.abscessus).

To assess the safety and efficacy of tigecycline in the treatment of drug resistant rapidly growing mycobacterial disease especially M. abscessus

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Mycobacterium Abscessus Lung Disease Rapidly Growing Mycobacterial Lung Disease

Interventions

TigecyclineDRUG

Tigecycline dosage based on age and clinical status of patient.

Eligibility

Sex: ALLMin age: 10 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Positive cultures for rapidly growing mycobacteria * Patients who have drug resistant isolates or are intolerant of macrolides or have serious infections unresponsive to currently available drugs * Adults and children 10 years of age and older * Pretreatment isolate of M. avium complex available for MIC determination * Available for followup appointments Exclusion Criteria: * History of tetracycline allergy * If a menstruating female, not pregnant and on adequate birth control

Locations (1)

The University of Texas Health Science Center at Tyler

Tyler, Texas, United States

Outcomes

Primary Outcomes

Clinical and microbiological outcomes such as clinical symptoms and laboratory cultures

culture neg X3 ( sputum conversion)

Time frame: 6 mos

Secondary Outcomes

clinical and Microbiological outcomes

clinical and radiographic improvements

Time frame: 6 mos

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.